RET and medullary thyroid gland carcinoma: The phase 3 LIBRETTO-531 trial (NCT04211337) further established selpercatinib’s efficacy in first-line treatment, showing superior PFS compared to physicians’ choice of cabozantinib and vandetanib in treating patients with advanced RET-mutant medullary thyroid cancer (mPFS: not reached vs. 16.8 [12.2–25.1] months; HR: 0.28 [0.16–0.48], p < 0.001) [7].